The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 17, 2018

Filed:

Jun. 26, 2014
Applicant:

The University of Western Ontario, London, CA;

Inventors:

Chil-Yong Kang, London, CA;

Gyoung Nyoun Kim, London, CA;

Assignee:

Other;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/39 (2006.01); A61K 39/12 (2006.01); C07K 14/005 (2006.01); C12N 15/86 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39 (2013.01); A61K 39/12 (2013.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); C12N 15/86 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/545 (2013.01); C12N 2740/16034 (2013.01); C12N 2760/20222 (2013.01); C12N 2760/20234 (2013.01); C12N 2760/20243 (2013.01); C12N 2770/24234 (2013.01);
Abstract

The present invention relates to vesicular stomatitis virus (VSV) matrix (M) protein mutants. One mutant M protein includes a glycine changed to a glutamic acid at position (21), a leucine changed to alanine at position (111) and a methionine changed to an arginine at position (51). Another M protein mutant includes a glycine changed to a glutamic acid at position (22) and a methionine changed to an arginine at positions (48) and (51). These new rVSVs having the mutant M are significantly attenuated and lost virulence, including neurovirulence, and are capable of inducing an immune responses against an antigen of interest. In addition, a rVSV serotype Indiana having the first described M mutant is capable of efficient replication at 31° C., and of poor replication or incapable of replication at about 37° C. or higher.


Find Patent Forward Citations

Loading…